IL-17 Role in Variants of Psoriasis
NCT02078297 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 90
Last updated 2015-03-27
Summary
The goal of this project is to study some mechanisms involved in the dysregulation of the immune system observed in the skin of subjects with psoriasis. This will be done by analyzing specific immune cells as well as gene and protein expression in small skin samples (biopsies) from patients with psoriasis. These results will be compared to the skin of healthy subjects without psoriasis.
Conditions
- Scalp Psoriasis
- Pustular Palmo-plantar Psoriasis
- Non-pustular Palmo-plantar Psoriasis
- Elbow Psoriasis
- Lower Leg Psoriasis
Sponsors & Collaborators
-
Innovaderm Research Inc.
lead OTHER
Principal Investigators
-
Robert Bissonnette, MD · Innovaderm Research
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2014-02-28
- Primary Completion
- 2015-02-28
- Completion
- 2015-03-31
Countries
- Canada
Study Locations
More Related Trials
-
Safety and Efficacy of Infliximab in Palmoplantar Psoriasis
NCT00629772 ·Status: COMPLETED ·Phase: PHASE3
-
The Impact of Targeted Therapy on Microorganism in Patients With Psoriasis
NCT01504113 ·Status: UNKNOWN
-
Cytokines and Vascular Inflammation in Psoriasis
NCT02305953 ·Status: COMPLETED
-
Exploratory Study on Quality of Life in Patient With Moderate Psoriasis and Moderate Psoriatic Arthritis
NCT01139918 ·Status: COMPLETED
-
Assessment of Long-Term Infliximab for Psoriasis (P05319)
NCT00779675 ·Status: COMPLETED
-
The Immunological Basis for Treatment Resistance to Anti-TNF Treatments
NCT01971346 ·Status: COMPLETED ·Phase: PHASE4
-
A Study of HS-20137 in Participants with Moderate-to-severe Plaque Psoriasis
NCT06844799 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
Study of Psoriatic Arthritis
NCT00001420 ·Status: COMPLETED
-
Association Between the Occurrence of a Clinical RElapse and Gut MIcrobiota Modifications: a Cohort Study of Patients With pSOriasis
NCT06055699 ·Status: NOT_YET_RECRUITING
-
A Study of Switching to Picankibart in Chinese Patients With Plaque Psoriasis With an Inadequate Response to Interleukin-17 Monoclonal Antibody Therapy
NCT06945107 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
The Association Between Psoriasis and Intestinal Bacterial Population
NCT02417792 ·Status: COMPLETED
-
Randomized Double-Blind Placebo-Controlled Trial Using Recombinant Human Interleukin-10 for Moderate-to-Severe Psoriasis
NCT00001797 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase 2 Study of Recombinant Anti-IL-17A Humanized Monoclonal Antibody in Chinese Participants With Moderate-to-Severe Plaque Psoriasis
NCT05604898 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study to Evaluate the Efficacy and Safety of Subcutaneous MK-3222, Followed by an Optional Long-Term Safety Extension Study, in Participants With Moderate-to-Severe Chronic Plaque Psoriasis (MK-3222-010)
NCT01722331 ·Status: COMPLETED ·Phase: PHASE3
-
Cell Responses to IFN-gamma
NCT01317017 ·Status: TERMINATED ·Phase: EARLY_PHASE1
-
A Phase 3 Study of Recombinant Anti-IL-17A Humanized Monoclonal Antibody in Chinese Participants With Moderate-to-Severe Plaque Psoriasis
NCT05536726 ·Status: COMPLETED ·Phase: PHASE3
-
Role of Chemokine and Chemokine Receptor in Psoriasis
NCT03302390 ·Status: WITHDRAWN
-
Apremilast in Palmo-Plantar Psoriasis
NCT02400749 ·Status: COMPLETED ·Phase: PHASE4
-
Personal Precise Treatment on Psoriasis and Psoriatic Arthritis
NCT04915105 ·Status: UNKNOWN ·Phase: NA
-
Assessing the Long Term Effectiveness and Safety of Biotherapies in the Treatment of Cutaneous Psoriasis
NCT01617018 ·Status: COMPLETED
-
Safety and Tolerability Study of COVA322 in Patients With Stable Chronic Moderate-to-severe Plaque Psoriasis
NCT02243787 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
A Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous Tildrakizumab (SCH 900222/MK-3222) in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Followed by a Long-term Extension Study (MK-3222-011)
NCT01729754 ·Status: COMPLETED ·Phase: PHASE3
-
First Human Dose Study of Anti-IL-20 in Psoriasis: A Study of Safety, Tolerability and Early Signals of Biologic and Clinical Effects
NCT01261767 ·Status: TERMINATED ·Phase: PHASE1
-
Single Cell Genomics of Psoriatic Skin
NCT02929745 ·Status: COMPLETED ·Phase: NA
-
A Study of the Safety and Efficacy of Infliximab in Patients With Psoriasis
NCT00106834 ·Status: COMPLETED ·Phase: PHASE3